1432135-75-5

Upstream product

• 121-87-9 2-Chloro-4-nitroaniline 
• 633328-33-3 3-bromo-1H-pyrazolo[4,3-b]pyridine 
• 272-52-6 1H-pyrazolo-[4,3-b]-pyridine 
• 881-87-8 N-(2-chloro-4-nitrophenyl)acetamide 
• 1432111-98-2 3-bromo-1-(4-methoxybenzyl)-1H-pyrazolo[4,3-b]pyridine 
• 57556-49-7 N-(4-Amino-2-chloro-phenyl)-acetamide 

Downstream Products

• 1432112-24-7 2-chloro-N⁴-[1-(4-methoxybenzyl)-1H-pyrazolo[4,3-b]pyridin-3-yl]benzene-1,4-diamine 
• 1432112-27-0 2-(2-chloro-4-{[1-(4-methoxybenzyl)-1H-pyrazolo[4,3-b]pyridin-3-yl]amino}phenyl)-1H-pyrrolo[3,4-c] pyridine-1,3(2H)-dione 
• 1432112-28-1 2-chloro-N-(2-chloro-4-{[1-(4-methoxybenzyl)-1H-pyrazolo[4,3-b]pyridin-3-yl]amino}phenyl)-4-fluorobenzamide 

Relevant academic research and scientific papers

ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS

Formula (I), and salts thereof, wherein R1, RA2, RA3 and RA4, are defined herein, which have properties for positive allosteric modulation of mGluR-4 receptor sites. Also described are pharmaceutical formulations comprising the compounds of Formula (I) or their salts, and methods of treating Parkinson's disease and related disorders using the same.

ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS

Disclosed are compounds of Formula (I), and salts thereof, wherein R1, RA2, RA3 and RA4, are defined herein, which have properties for positive allosteric modulation of mGluR-4 receptor sites. Also described are pharmaceutical formulations comprising the compounds of Formula (I) or their salts, and methods of treating Parkinson's disease and related disorders using the same.